Braemar Hotels & Resorts Reports Q4 Loss, Sells The Clancy for $115M Amidst Strategic Review

summarizeSummary

Braemar Hotels & Resorts reported a Q4 2025 net loss of $(46.0) million and completed the sale of The Clancy hotel for $115 million, a major step in its ongoing strategic review and company sale process.

check_boxKey Events

• Reports Q4 and Full Year 2025 Financial Results

  The company reported a net loss attributable to common stockholders of $(46.0) million or $(0.67) per diluted share for Q4 2025, and $(72.7) million or $(1.07) per diluted share for the full year 2025. Adjusted FFO was $(0.02) per diluted share for Q4 2025 and $0.28 for the full year. Comparable RevPAR for all hotels was relatively flat for Q4 and increased 1.0% for the full year.

• Completes Sale of The Clancy Hotel for $115 Million

  During Q4 2025, Braemar Hotels & Resorts completed the sale of its 410-room The Clancy hotel in San Francisco for $115 million. This significant asset disposition provides substantial capital and is a key action within the company's strategic review.

• Records $54.5 Million Impairment Charge

  The company recognized impairment charges of $54.492 million during the fourth quarter ended December 31, 2025.

• Reiterates Ongoing Company Sale Process and Dividend Suspension

  The company confirmed that the process for the sale of the company, initiated in August 2025, is ongoing. In light of this, the common equity dividend policy for 2026 remains suspended, a decision previously announced on February 2, 2026.

auto_awesomeAnalysis

Braemar Hotels & Resorts Inc. reported a widened net loss for both Q4 and the full year 2025, alongside an impairment charge of $54.5 million in Q4. However, the most significant development is the completion of the sale of The Clancy hotel for $115 million during the fourth quarter. This substantial asset disposition, representing over 50% of the company's market capitalization, provides significant liquidity and is a concrete step in the previously announced process for the sale of the company. The filing also reiterates the suspension of the common stock dividend policy for 2026 due to this ongoing strategic review. This news comes amidst recent corporate governance challenges, including director resignations and activist investor pressure, making the execution of this asset sale a critical development for the company's strategic direction and financial flexibility.